Calixa Therapeutics

Meeting the growing threat of drug-resistant Gram negative bacteria through innovative therapeutics

Calixa was founded in 2007 to develop novel antibiotics to treat serious hospital-based bacterial infections. The company's lead asset was a combination of a novel 5th-generation cephalosporin with a beta lactamase inhibitor, and the drug displayed an outstanding spectrum of activity against Gram negative bacteria including resistant isolates. Calixa was acquired by Cubist Pharmaceuticals in 2009, and Cubist gained approval for Calixa's lead asset (brand name Zerbaxa) in 2014 to treat complicated intra-abdominal infections and complicated urinary tract infections.


Acquired by Cubist Pharmaceuticals in 2009

Year of Investment



Life Sciences


Development-Stage Therapeutics


Bay Area, California

Frazier Team